Ciro Romano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5175647/publications.pdf

Version: 2024-02-01

279487 233125 2,187 45 65 23 citations h-index g-index papers 66 66 66 3264 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Does poor glycaemic control affect the immunogenicity of the ⟨scp⟩COVIDâ€19⟨/scp⟩ vaccination in patients with type ⟨scp⟩2⟨/scp⟩ diabetes: The ⟨scp⟩CAVEAT⟨/scp⟩ study. Diabetes, Obesity and Metabolism, 2022, 24, 160-165.	2.2	75
2	Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study. Clinical Infectious Diseases, 2022, 75, e403-e409.	2.9	40
3	Comparison of Timing to Develop Anti-Drug Antibodies to Infliximab and Adalimumab Between Adult and Pediatric Age Groups, Males and Females. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 63-71.	0.3	8
4	Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. Frontiers in Immunology, 2022, 13, 882064.	2.2	7
5	Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early) Tj ETQq1 1 0.78431	.4 rgBT	/Oveglock 10 Ts
6	Safety and Effectiveness of Dupilumab in Prurigo Nodularis. Journal of Investigational Allergology and Clinical Immunology, 2021, 31, 162-163.	0.6	14
7	Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opinion on Biological Therapy, 2021, 21, 661-674.	1.4	4
8	Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Review of Gastroenterology and Hepatology, 2021, 15, 643-656.	1.4	8
9	Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. Minerva Medica, 2021, 112, 246-254.	0.3	2
10	Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients. Journal of Scleroderma and Related Disorders, 2021, 6, 256-263.	1.0	2
11	Detection of neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines. Annals of Allergy, Asthma and Immunology, 2021, 127, 499-501.	0.5	16
12	Authors' response. Annals of Allergy, Asthma and Immunology, 2021, 127, 703-704.	0.5	0
13	Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy. European Review for Medical and Pharmacological Sciences, 2021, 25, 3623-3631.	0.5	2
14	Choosing the most appropriate biologic therapy for Crohn's disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy, 2020, 20, 49-62.	1.4	6
15	Omalizumab as aÂlast resort therapy for intractable, severe chronic allergic rhinosinusitis. Allergo Journal International, 2019, 28, 99-102.	0.9	2
16	AB0648â€CORRELATIONS BETWEEN NEUTROPHIL/LYMPHOCYTE RATIO AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
17	Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients. Clinical Rheumatology, 2018, 37, 1695-1700.	1.0	18
18	Plantar Kaposi Sarcoma Revealed by Antisynthetase Syndrome. Journal of Clinical Rheumatology, 2018, 24, 281-285.	0.5	1

#	Article	IF	CITATIONS
19	Uncommon immune-mediated extrahepatic manifestations of HCV infection. Expert Review of Clinical Immunology, 2018, 14, 1089-1099.	1.3	11
20	Chronic Hepatitis C Virus Infection and Depression. Clinics in Liver Disease, 2017, 21, 517-534.	1.0	46
21	Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 1764-1774.	0.9	49
22	Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: A brief case-based review. European Journal of Rheumatology, 2017, 4, 231-233.	1.3	5
23	Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria: a preliminary report. European Annals of Allergy and Clinical Immunology, 2017, 49, 171.	0.4	1
24	Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. ESMO Open, 2016, 1, e000038.	2.0	66
25	Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. World Journal of Gastroenterology, 2015, 21, 2269.	1.4	134
26	Omalizumab for Difficult-to-Treat Dermatological Conditions: Clinical and Immunological Features from a Retrospective Real-Life Experience. Clinical Drug Investigation, 2015, 35, 159-168.	1.1	30
27	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence. Oncology Letters, 2015, 9, 542-550.	0.8	18
28	Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. Surgery, 2015, 158, 112-120.	1.0	71
29	Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia. International Journal of Hematology, 2015, 101, 67-74.	0.7	10
30	Omalizumab therapy for children and adolescents with severe allergic asthma. Expert Review of Clinical Immunology, $2015, 11, 1309-1319$.	1.3	4
31	Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer Patients. Journal of Gastrointestinal Surgery, 2013, 17, 1809-1818.	0.9	45
32	Granulomatous Lobular Mastitis: Another Manifestation of Systemic Lupus Erythematosus?. Breast Journal, 2013, 19, 331-332.	0.4	8
33	Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World Journal of Hepatology, 2013, 5, 528.	0.8	178
34	Clinically-Irrelevant Positivity for Serum Proteinase 3-ANCA in HIV Disease. International Journal of Immunopathology and Pharmacology, 2013, 26, 957-959.	1.0	5
35	Behavior of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Colon Cancer Patients Undergoing Surgery. Journal of Clinical Immunology, 2011, 31, 1095-1104.	2.0	38
36	A subtle case of iron-deficiency anemia. Internal and Emergency Medicine, 2011, 6, 191-192.	1.0	0

#	Article	IF	Citations
37	Lupus Mastitis in Systemic Lupus Erythematosus: A Rare Condition Requiring a Minimally Invasive Diagnostic Approach. International Journal of Immunopathology and Pharmacology, 2011, 24, 1125-1129.	1.0	7
38	Maintenance of Remission With Low-Dose Omalizumab in Long-Lasting, Refractory Chronic Urticaria. Annals of Allergy, Asthma and Immunology, 2010, 104, 95-97.	0.5	32
39	A Scleroderma-Like Cutaneous Syndrome Associated With a Marked Th2-Type Immune Response Occurring After a Prosthetic Joint Implant. Journal of Clinical Rheumatology, 2009, 15, 133-137.	0.5	3
40	T-2 toxin immunotoxicity on human B and T lymphoid cell lines. Toxicology, 2005, 210, 81-91.	2.0	58
41	Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. Immunology Letters, 2005, 97, 131-139.	1.1	19
42	Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas. Clinical Cancer Research, 2004, 10, 3490-3499.	3.2	103
43	Prognostic Value of p27, p53, and Vascular Endothelial Growth Factor in Dukes A and B Colon Cancer Patients Undergoing Potentially Curative Surgery. Diseases of the Colon and Rectum, 2004, 47, 1904-1914.	0.7	30
44	Primary cardiac T-cell lymphoma. Annals of Hematology, 2004, 83, 450-454.	0.8	46
45	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer, 2004, 100, 270-278.	2.0	100
46	Normal Interleukin-10 Serum Level Opposed to High Serum Levels of Carbohydrate Antigen 19-9 and Cancer Antigens 125 and 50 in a Case of True Splenic Cyst. Archives of Medical Research, 2003, 34, 145-148.	1.5	12
47	Effects of Stress Hyperglycemia on Acute Myocardial Infarction: Role of inflammatory immune process in functional cardiac outcome. Diabetes Care, 2003, 26, 3129-3135.	4.3	153
48	Effects of Preactivated Autologous T Lymphocytes on CD80, CD86 and CD95 Expression by Chronic Lymphocytic Leukemia B Cells. Leukemia and Lymphoma, 2003, 44, 1963-1971.	0.6	14
49	A True Splenic Cyst Producing Carbohydrate Antigen 19-9 and Cancer Antigens 50 and 125, but Not Interleukin 10. Digestive Surgery, 2003, 20, 71-74.	0.6	7
50	Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells. Oncology Reports, 2003, 10, 653-8.	1.2	4
51	Efficacy of L-Carnitine in Reducing Hyperammonaemia and Improving Neuropsychological Test Performance in Patients with Hepatic Cirrhosis. Clinical Drug Investigation, 2002, 22, 7-14.	1.1	11
52	Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery. Clinical Immunology, 2002, 102, 169-178.	1.4	196
53	Relationship between total and allergen-specific IgE serum levels and presence of symptoms in farm workers sensitized to Tetranychus urticae. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 1044-1047.	2.7	7
54	Circulating Levels of Interleukin-10 and Interleukin-6 in Gastric and Colon Cancer Patients Before and After Surgery: Relationship with Radicality and Outcome. Journal of Interferon and Cytokine Research, 2002, 22, 473-482.	0.5	60

#	Article	IF	CITATIONS
55	Altered constitutive and activation-induced expression of CD95 by B- and T-cells in B-cell chronic lymphocytic leukemia. Haematologica, 2002, 87, 325-7.	1.7	2
56	Long-term absence of sensitization to mepivacaine as assessed by a diagnostic protocol including patch testing. Clinical and Experimental Allergy, 2001, 31, 1762-1770.	1.4	15
57	Epidemiology of allergic occupational diseases induced by Tetranychus urticae in greenhouse and open-field farmers living in a temperate climate area. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 1157-1163.	2.7	9
58	Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic Indicator. Journal of Interferon and Cytokine Research, 2001, 21, 45-52.	0.5	76
59	Semiallogeneic Cell Hybrids as Therapeutic Vaccines for Cancer. Journal of Immunotherapy, 2000, 23, 246-254.	1.2	16
60	Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunology, Immunotherapy, 2000, 49, 530-536.	2.0	51
61	Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients. Chest, 2000, 117, 365-373.	0.4	139
62	Lymphoblastoid \hat{l} ±-IFN, leukocytic \hat{l} ±-IFN and natural \hat{l}^2 -IFN in the treatment of chronic hepatitis C: a clinical comparison of 150 cases. Hepatology Research, 1999, 15, 225-237.	1.8	3
63	Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. , 1999, 86, 1936-1943.		75
64	Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies., 1999, 86, 1936.		4
65	Eosinophilia triggered by \hat{l}^2 -interferon therapy for chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 1997, 9, 909-911.	0.8	7